Amrubicin (AMR) : : 9-amino-anthracycline

Phase II Trial of Amrubicin (AMR) for Recurrent or Refractory SCLC (ASCO)
ASCO 2006 abstract of a phase II study that found amrubicin is a well-tolerated and promising treatment for recurrent or refractory SCLC. The authors recommend further evaluation in a phase III trial. [5/06]

Amrubicin & SCLC - Recent MEDLINE Abstracts

Amrubicin - Clinical Trials (ClinicalTrials.gov)